Cargando…
Interleukin‐22 in urinary tract disease – new experimental directions
Interleukin (IL)‐22 is expressed by immune cells in the urinary tract and IL‐22 receptor is expressed in urothelium and renal tubule cells. IL‐22 can be specifically targeted in the urinary tract or conditionally depleted in mice and targeted therapeutically in humans.[Image: see text]
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276185/ https://www.ncbi.nlm.nih.gov/pubmed/32523694 http://dx.doi.org/10.1002/cti2.1143 |
| _version_ | 1783542913667432448 |
|---|---|
| author | Ingersoll, Molly A Starkey, Malcolm R |
| author_facet | Ingersoll, Molly A Starkey, Malcolm R |
| author_sort | Ingersoll, Molly A |
| collection | PubMed |
| description | Interleukin (IL)‐22 is expressed by immune cells in the urinary tract and IL‐22 receptor is expressed in urothelium and renal tubule cells. IL‐22 can be specifically targeted in the urinary tract or conditionally depleted in mice and targeted therapeutically in humans.[Image: see text] |
| format | Online Article Text |
| id | pubmed-7276185 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72761852020-06-09 Interleukin‐22 in urinary tract disease – new experimental directions Ingersoll, Molly A Starkey, Malcolm R Clin Transl Immunology News and Commentary Interleukin (IL)‐22 is expressed by immune cells in the urinary tract and IL‐22 receptor is expressed in urothelium and renal tubule cells. IL‐22 can be specifically targeted in the urinary tract or conditionally depleted in mice and targeted therapeutically in humans.[Image: see text] John Wiley and Sons Inc. 2020-06-07 /pmc/articles/PMC7276185/ /pubmed/32523694 http://dx.doi.org/10.1002/cti2.1143 Text en © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | News and Commentary Ingersoll, Molly A Starkey, Malcolm R Interleukin‐22 in urinary tract disease – new experimental directions |
| title | Interleukin‐22 in urinary tract disease – new experimental directions |
| title_full | Interleukin‐22 in urinary tract disease – new experimental directions |
| title_fullStr | Interleukin‐22 in urinary tract disease – new experimental directions |
| title_full_unstemmed | Interleukin‐22 in urinary tract disease – new experimental directions |
| title_short | Interleukin‐22 in urinary tract disease – new experimental directions |
| title_sort | interleukin‐22 in urinary tract disease – new experimental directions |
| topic | News and Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276185/ https://www.ncbi.nlm.nih.gov/pubmed/32523694 http://dx.doi.org/10.1002/cti2.1143 |
| work_keys_str_mv | AT ingersollmollya interleukin22inurinarytractdiseasenewexperimentaldirections AT starkeymalcolmr interleukin22inurinarytractdiseasenewexperimentaldirections |